20
Participants
Start Date
April 18, 2017
Primary Completion Date
March 25, 2020
Study Completion Date
March 25, 2020
Olaptesed pegol - Monotherapy
"Monotherapy (MT) period:~Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
Olaptesed pegol + Pembrolizumab - Combination Therapy
"Combination therapy (CT) period:~Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg
Merck Sharp & Dohme LLC
INDUSTRY
TME Pharma AG
INDUSTRY